Co-delivery of GOLPH3 siRNA and gefitinib by cationic lipid-PLGA nanoparticles improves EGFR-targeted therapy for glioma
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Co-delivery of GOLPH3 siRNA and gefitinib by cationic lipid-PLGA nanoparticles improves EGFR-targeted therapy for glioma
Authors
Keywords
-
Journal
JOURNAL OF MOLECULAR MEDICINE-JMM
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-10-31
DOI
10.1007/s00109-019-01843-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Enhanced anti-tumor efficacy of temozolomide-loaded carboxylated poly(amido-amine) combined with photothermal/photodynamic therapy for melanoma treatment
- (2018) Jianqin Tang et al. CANCER LETTERS
- A glial blueprint for gliomagenesis
- (2018) Dylan Laug et al. NATURE REVIEWS NEUROSCIENCE
- Current Challenges and Opportunities in Treating Glioblastoma
- (2018) Andrea Shergalis et al. PHARMACOLOGICAL REVIEWS
- Prognostic significance of epidermal growth factor receptor expression in glioma patients
- (2018) Junhong Li et al. OncoTargets and Therapy
- Inhibition of glioma growth by a GOLPH3 siRNA-loaded cationic liposomes
- (2018) Zixuan Yuan et al. JOURNAL OF NEURO-ONCOLOGY
- Primary brain tumours in adults
- (2018) Sarah Lapointe et al. LANCET
- Functionalized Cu3BiS3 nanoparticles for dual-modal imaging and targeted photothermal/photodynamic therapy
- (2018) Yanke Wang et al. Nanoscale
- Hypoxia-responsive ionizable liposome delivery siRNA for glioma therapy
- (2017) Hong-Mei Liu et al. International Journal of Nanomedicine
- PDGFA/PDGFRα-regulated GOLM1 promotes human glioma progression through activation of AKT
- (2017) Ran Xu et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Phase II trial of dacomitinib, a pan–human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification
- (2017) Juan Manuel Sepúlveda-Sánchez et al. NEURO-ONCOLOGY
- Golgi phosphoprotein 3 promotes glioma progression via inhibiting Rab5-mediated endocytosis and degradation of epidermal growth factor receptor
- (2017) Xiuping Zhou et al. NEURO-ONCOLOGY
- Internalized CD44s splice isoform attenuates EGFR degradation by targeting Rab7A
- (2017) Wei Wang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Blood–Brain-Barrier-Penetrating Albumin Nanoparticles for Biomimetic Drug Delivery via Albumin-Binding Protein Pathways for Antiglioma Therapy
- (2016) Tingting Lin et al. ACS Nano
- Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082)
- (2016) W. Wick et al. CLINICAL CANCER RESEARCH
- Angiopep2-functionalized polymersomes for targeted doxorubicin delivery to glioblastoma cells
- (2016) Patrícia Figueiredo et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- The effect of nanoparticle size on in vivo pharmacokinetics and cellular interaction
- (2016) Nazanin Hoshyar et al. Nanomedicine
- Epidermal growth factor receptor targeting and challenges in glioblastoma
- (2016) Amy Haseley Thorne et al. NEURO-ONCOLOGY
- PTEN modulates EGFR late endocytic trafficking and degradation by dephosphorylating Rab7
- (2016) Swapnil Rohidas Shinde et al. Nature Communications
- Encapsulation of temozolomide in a tumor-targeting nanocomplex enhances anti-cancer efficacy and reduces toxicity in a mouse model of glioblastoma
- (2015) Sang-Soo Kim et al. CANCER LETTERS
- Co-delivery of doxorubicin and siRNA for glioma therapy by a brain targeting system: angiopep-2-modified poly(lactic-co-glycolic acid) nanoparticles
- (2015) Lei Wang et al. JOURNAL OF DRUG TARGETING
- Dual-Targeting Upconversion Nanoprobes across the Blood–Brain Barrier for Magnetic Resonance/Fluorescence Imaging of Intracranial Glioblastoma
- (2014) Dalong Ni et al. ACS Nano
- Low-Density Lipoprotein Receptor–Related Protein-1
- (2014) Dudley K. Strickland et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- SiRNA-phospholipid conjugates for gene and drug delivery in cancer treatment
- (2014) Hongmei Liu et al. BIOMATERIALS
- A single-institution phase II trial of radiation, temozolomide, erlotinib, and bevacizumab for initial treatment of glioblastoma
- (2014) J. L. Clarke et al. NEURO-ONCOLOGY
- Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02
- (2014) P. Y. Wen et al. NEURO-ONCOLOGY
- Protein tyrosine phosphatase PTPN3 inhibits lung cancer cell proliferation and migration by promoting EGFR endocytic degradation
- (2014) M-Y Li et al. ONCOGENE
- Gefitinib loaded folate decorated bovine serum albumin conjugated carboxymethyl-beta-cyclodextrin nanoparticles enhance drug delivery and attenuate autophagy in folate receptor-positive cancer cells
- (2014) Yijie Shi et al. JOURNAL OF NANOBIOTECHNOLOGY
- The Somatic Genomic Landscape of Glioblastoma
- (2013) Cameron W. Brennan et al. CELL
- Nanotechnology for CNS delivery of bio-therapeutic agents
- (2013) Lipa Shah et al. Drug Delivery and Translational Research
- RTOG 0211: A Phase 1/2 Study of Radiation Therapy With Concurrent Gefitinib for Newly Diagnosed Glioblastoma Patients
- (2012) Arnab Chakravarti et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Influence of glioma tumour microenvironment on the transport of ANG1005 via low-density lipoprotein receptor-related protein 1
- (2011) Y Bertrand et al. BRITISH JOURNAL OF CANCER
- Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinib--A Phase II Trial
- (2011) M. E. Hegi et al. MOLECULAR CANCER THERAPEUTICS
- Current prospects for RNA interference-based therapies
- (2011) Beverly L. Davidson et al. NATURE REVIEWS GENETICS
- Feedback regulation of EGFR signalling: decision making by early and delayed loops
- (2011) Roi Avraham et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Aberrant Signaling Pathways in Glioma
- (2011) Mitsutoshi Nakada et al. Cancers
- Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma
- (2010) M.-d.-M. Inda et al. GENES & DEVELOPMENT
- Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP
- (2010) Nienke A. de Vries et al. INVESTIGATIONAL NEW DRUGS
- Discovery ofN-(4-Methoxyphenyl)-N,2-dimethylquinazolin-4-amine, a Potent Apoptosis Inducer and Efficacious Anticancer Agent with High Blood Brain Barrier Penetration
- (2009) Nilantha Sirisoma et al. JOURNAL OF MEDICINAL CHEMISTRY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started